Targeting bone as a therapy for myeloma.

about

Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics

P2860

Q34038854-4AD5C84D-C628-4672-87C5-CBFF9BC59FD0

P2860

Targeting bone as a therapy for myeloma.

Item

http://www.wikidata.org/entity/Q35603128

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Targeting bone as a therapy for myeloma.

@ast

Targeting bone as a therapy for myeloma.

@en

type

Item

label

Targeting bone as a therapy for myeloma.

@ast

Targeting bone as a therapy for myeloma.

@en

prefLabel

Targeting bone as a therapy for myeloma.

@ast

Targeting bone as a therapy for myeloma.

@en

P1476

Targeting bone as a therapy for myeloma

@en

P2093

Ping Wu

http://www.w3.org/2001/XMLSchema#string

P2860

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.

Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

P2888

s12307-011-0079-2

P304

299-311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12307-011-0079-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gareth J Morgan

P577

2011-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51563914

http://www.w3.org/2001/XMLSchema#string

P698

21833747

http://www.w3.org/2001/XMLSchema#string

P932

3234321

http://www.w3.org/2001/XMLSchema#string

Targeting bone as a therapy for myeloma.

about

P2860

P2860

Targeting bone as a therapy for myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932